DESITIN - SUCCESS IN CNS

27.09.2010

Two new products joined Desitin's addiction portfolio in September 2010.

1) Adepend® the first Naltrexon for treatment of alcohol addiction*

2) CRAS® the first generic Buprenorphin for the treatment of opioid addiction

 

We are proud to enlarge our product portfolio in the area of addiction and to support patients with alcohol or opioid addiction with new therapeutic options.

We want to sensitize people to the dangers of alcohol or opioid drugs.

 

*Adepend® is indicated for the reduction of relapse risk, for the support of abstinence and for the reduction of alcohol cravings as part of a comprehensive treatment in adults.